iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
2.005
-0.055 (-2.67%)
Apr 1, 2025, 10:21 AM EDT - Market open
iCAD, Inc. Revenue
In the year 2024, iCAD, Inc. had annual revenue of $19.61M with 13.22% growth. iCAD, Inc. had revenue of $5.41M in the quarter ending December 31, 2024, with 14.09% growth.
Revenue (ttm)
$19.61M
Revenue Growth
+13.22%
P/S Ratio
2.77
Revenue / Employee
$284,174
Employees
69
Market Cap
52.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.61M | 2.29M | 13.22% |
Dec 31, 2023 | 17.32M | -2.48M | -12.54% |
Dec 31, 2022 | 19.80M | -13.84M | -41.13% |
Dec 31, 2021 | 33.64M | 3.94M | 13.27% |
Dec 31, 2020 | 29.70M | -1.64M | -5.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ICAD News
- 12 days ago - iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 - GlobeNewsWire
- 26 days ago - iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America - GlobeNewsWire
- 4 weeks ago - Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025 - GlobeNewsWire
- 5 weeks ago - iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025 - GlobeNewsWire
- 2 months ago - iCAD Pre-Announces Estimated Q4 2024 Revenue - GlobeNewsWire
- 2 months ago - Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions - Newsfile Corp
- 3 months ago - SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations - GlobeNewsWire